Albert David Limited enters into co-marketing agreement for Placenta Products

Placentrex, the human placental extract product, is an old and well-established product of Albert David Limited ("Albert David"). It is used by the Gynecologists for PID (Pelvic Inflammatory Disease) and by Surgeons, Physicians and other doctors for difficult to heal wounds.

Co-Marketing is a well-established strategic process used by "parent companies" to help expand the product reach/market, thus offering the product benefits to a larger number of end users. We at Albert David too have decided to partner with Corona Remedies Private Limited to help take the 'Placenta Products (Placentrex)', with another brand name, to a larger and wider group of end beneficiaries.

With the above objective, Albert David Limited and Corona Remedies Private Limited have entered into a strategic Co-Marketing Agreement on 4" October, 2021.

Shares of Albert David Ltd., was last trading in BSE at Rs. 591.25 as compared to the previous close of Rs. 597.6. The total number of shares traded during the day was 468 in over 76 trades.

The stock hit an intraday high of Rs. 603.8 and intraday low of 591.25. The net turnover during the day was Rs. 279103.

Source : Equity Bulls

Keywords